The North America Human Alpha-1 Proteinase Inhibitor is experiencing steady growth due to increasing awareness of rare genetic disorders, rising healthcare expenditure, and the presence of advanced healthcare infrastructure across the US and Canada. The region benefits from early diagnosis initiatives, strong government support for orphan drug development, and continuous technological...